Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon’s Fentora Approved For Breakthrough Cancer Pain

This article was originally published in The Pink Sheet Daily

Executive Summary

Barr is free to launch generic of Actiq, Fentora’s predecessor.

You may also be interested in...



Cephalon’s Fentora sNDA Gets FDA Advisory Panel Review

Company tells “The Pink Sheet” DAILY advisory committee meeting slated for May 6 is routine for schedule II opioids.

Cephalon’s Fentora sNDA Gets FDA Advisory Panel Review

Company tells “The Pink Sheet” DAILY advisory committee meeting slated for May 6 is routine for schedule II opioids.

Cephalon Submits Fentora sNDA For Chronic Pain

Application includes strengthened risk management plan to ensure appropriate patient use and dosing, a critical concern after deaths were reported following unapproved uses.

Related Content

Topics

UsernamePublicRestriction

Register

PS064916

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel